Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Villejuif Cedex、フランス
- 1239.14.3301A Boehringer Ingelheim Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Patients with confirmed histological or cytological diagnosis of advanced solid tumours and for whom no proven therapy exists or who are not amenable to established treatments.
- Age 18 years or older.
- Life expectancy of at least three months.
- Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
- Patients previously treated and with asymptomatic brain metastases are eligible
- Patients must have recovered from recent surgery.
Exclusion criteria:
- Active infectious disease
- Recent surgery within the last 4 weeks prior visit 1.
- Chronic diarrhoea or gastrointestinal tract disease resulting in an inability to take oral medication
- History of haemorrhagic or thrombotic events
- Significant cardiovascular diseases within
- Current peripheral neuropathy > Common Terminology Criteria for Adverse Events (CTCAE) grade 1 except due to trauma
- Untreated or symptomatic brain metastases or leptomeningeal disease.
- Treatment with an Epidermal growth Factor-receptor (EGFR)- or Heregulin Receptor 2 (HER2) inhibiting drug or antiangiogenic drug.
- Therapeutic anticoagulation.
- Female patients of childbearing potential.
- Known pre-existing interstitial lung disease
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
実験的:BIBW 2992 + BIBF 1120
This is a phase I dose escalation clinical trial and the data obtained shall determine the MTD for the combination of BIBW 2992/BIBF 1120 in 28-day of treatment.
|
VEGF阻害剤
EGFR inhibitor
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Maximum Tolerated Dose (MTD) of Nintedanib and Afatinib Based on the Percentage of Participants Experienced Dose Limiting Toxicities
時間枠:first treatment cycle, up to 28 days
|
Maximum tolerated dose (MTD) of nintedanib and afatinib based on the Percentage of participants experienced dose limiting toxicities during the dose escalation phase.
|
first treatment cycle, up to 28 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Overall Tumour Response Rate Assessed by the Investigator According to the Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1
時間枠:6 weeks
|
The investigator evaluated whether complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) occurred in a patient. CR for target lesions: Disappearance of all target lesions. CR for non-target lesions: Disappearance of all non-target lesions and normalization of tumour marker level. All lymph nodes must be non-pathological in size (<10mm short axis). PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as references the smallest SoD while on study. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions |
6 weeks
|
Incidence and Intensity of Adverse Events According to CTCAE (Common Toxicity Criteria Adverse Event) Version 3.0
時間枠:First treatment administration until cut-off date of 02Oct2014; up to 336 days
|
Incidence and intensity of Adverse Events with grading according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0).
|
First treatment administration until cut-off date of 02Oct2014; up to 336 days
|
Changes in Safety Laboratory Parameters
時間枠:First treatment administration until cut-off date of 02 October 2014, up to 336 days
|
Changes in safety laboratory Parameters reported as adverse events
|
First treatment administration until cut-off date of 02 October 2014, up to 336 days
|
Cpre,ss,Norm (Dose Normalized Trough Plasma Concentration of Nintedanib at Steady State)
時間枠:Day 8, Day 15, Day 22 and Day 28
|
Cpre,ss,norm (Dose normalized trough plasma concentration of nintedanib at steady state) are presented for the 2 MTD treatment groups (continuous administered nintedanib at 150 mg b.i.d. concomitantly with continuously administered afatinib 30 mg q.d. or with intermittently administered afatinib 40 mg q.d.) As nintedanib is given twice daily, samples are taken at Day 8, Day 15, Day 22 and Day 28; the Pharmacokinetic (PK) parameter names will be Cpre,ss,15,norm (Day 8), Cpre,ss,29,norm (Day 15), Cpre,ss,43,norm (Day 22) and Cpre,ss,55,norm (Day 28) |
Day 8, Day 15, Day 22 and Day 28
|
Trough Plasma Concentration of Afatinib at Steady State
時間枠:Day 7, Day 13, Day 15, Day 22, Day 27 and Day 28
|
C(pre,ss) is defined as pre-dose (trough) concentration of afatinib in plasma at steady state immediately before administration of the next dose. C24,7 corresponds to the plasma concentration at 24 hours on Day 7. C24,13 corresponds to the plasma concentration at 24 hours on Day 13. C24,27 corresponds to the plasma concentration at 24 hours on Day 27. |
Day 7, Day 13, Day 15, Day 22, Day 27 and Day 28
|
Objective Response (OR) During the Expansion Phase
時間枠:Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
OR is defined as a best overall response of complete response (CR) or partial response (PR) according to RECIST version 1.1, CR for target lesions (TL): Disappearance of all target lesions. CR for non-target lesions (NTL): Disappearance of all non-target lesions. All lymph nodes must be nonpathological in size (<10mm short axis). PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters. Other factors which add to the overall response of an imaging timepoint as PR are as below: CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; All the above scenarios should also satisfy 'No occurrence of new lesions'. |
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Disease Control (DC) During the Expansion Phase
時間枠:Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
DC is defined as the best overall response of CR, PR, stable disease (SD) and non-CR/non-PD.
CR for target lesions (TL): Disappearance of all target lesions.
CR for non-target lesions (NTL): Disappearance of all non-target lesions .
All lymph nodes must be non-pathological in size (<10mm short axis).
PR for TL: At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters.
Other factors which add to the overall response of an imaging timepoint as PR are as below:- CR in TL, but non-CR/Non-PD in NTL leads to PR CR in TL, but not evaluated NTL leads to PR PR in TL, but non-PD NTL or not all evaluated NTL leads to PR; SD for TL: change in the sum of diameters does not satisfy PR or PD.
SD in TL, non-PD in NTL lead to overall response of SD, provided there is no appearance of new lesions.
|
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Stable Disease for at Least 12 Weeks During the Expansion Phase
時間枠:Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
SD: Neither sufficient shrinkage to qualify for PR (Partial response) nor sufficient increase to qualify for PD(Progressive disease), taking as references the smallest sum of diameters SoD while on study. PR: At least a 30% decrease in the sum of diameters (SoD) of target lesions taking as reference the baseline sum diameters. PD: At least a 20% increase in the SoD of target lesions, taking as references the smallest sum on study (this includes the baseline sum if that is the smallest on study). Also, the sum must also demonstrate an absolute increase of a least 5mm. Appearance of one or more new lesions. |
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Percentage Change in the Tumour Size From Baseline During the Expansion Phase
時間枠:Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
Percentage change in the tumour size from baseline is expressed as Number of subjects with maximum decrease from baseline in the sum of longest diameters of target lesions.
|
Tumour assessment was to be performed at Screening, every 6 weeks after starting study treatment until disease progression, and at the end-of-treatment (EOT) visit (up to 1117 days)
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
BIBF1120の臨床試験
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)完了再発子宮体がん | 子宮内膜明細胞腺癌 | 子宮内膜漿液性腺癌 | 子宮内膜未分化がん | 子宮内膜腺癌 | 子宮内膜移行上皮がん | 子宮内膜粘液腺癌 | 子宮内膜扁平上皮がん | 悪性子宮体混合上皮性および間葉性新生物アメリカ
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)完了
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer Ingelheim完了再発非小細胞肺がん | IV期の非小細胞肺がん | 扁平上皮肺がん | III期の非小細胞肺がんアメリカ
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive Cancer Network完了再発結腸癌 | 再発直腸癌 | 直腸腺癌 | 結腸腺癌 | IVA期の結腸がん | IVA期の直腸がん | IVB期の結腸がん | ステージ IVB 直腸がんアメリカ
-
Roswell Park Cancer InstituteNational Comprehensive Cancer Network完了
-
Boehringer Ingelheim完了肺線維症アルゼンチン, オーストラリア, ベルギー, ブラジル, ブルガリア, カナダ, チリ, 中国, チェコ共和国, フランス, ドイツ, ギリシャ, ハンガリー, アイルランド, イタリア, 大韓民国, メキシコ, オランダ, ポルトガル, ロシア連邦, 南アフリカ, スペイン, 台湾, 七面鳥, イギリス